ZYLOX Hippo PTA Balloon Dilatation Catheter
Zylox Medtech Co., Ltd. · Decision date Sep 21, 2026
What did the FDA decide?
The FDA recorded a decision of SESE for application K260416, titled ZYLOX Hippo PTA Balloon Dilatation Catheter, dated 2026-09-21. The applicant is Zylox Medtech Co., Ltd., the specialty is listed as Cardiovascular, and the product code is LIT. In 510(k) practice, SESE denotes a substantially equivalent determination, meaning clearance rather than premarket approval of a new device.
The available excerpt from the decision letter states that the catheter is also indicated for post-dilatation of stents and stent grafts in the peripheral vasculature. The excerpt does not identify a predicate device, the specific component or modification under review, or the full indications cleared, so those details remain unknown from this record. The letter also notes that some cleared products may be combination products rather than devices.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 21, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260416
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Zylox Medtech Co., Ltd.
- Product code
- LIT
- Decision code
- SESE
- Decision date
- Sep 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, Angioplasty, Peripheral, Transluminal.
- Applicant
- Zylox Medtech Co., Ltd.
- Product code
- LIT
- FDA device class
- 2
FDA decision timeline
K260416 received
Application receipt date recorded by FDA.
K260416 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code LIT
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Brosmed Medical Co., Ltd. | 510(k) clearance | Nov 2, 2026 | FDA | |
| Kossel Medtech (Suzhou) Co., Ltd. | 510(k) clearance | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Zylox Medtech Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Hangzhou
Sources and methodology
- Original FDA record: K260416
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records